What is Ebola Virus – When to Worry and When to See a Doctor

1. What is Ebola Virus?

A severe illness: Ebola virus disease (EVD) is a rare but potentially life-threatening Viral Haemorrhagic Fever (VHF; see below) affecting humans and other primates.

Historical origins: Ebola was first identified in 1976 in two simultaneous outbreaks, one in a village near the Ebola River in the Democratic Republic of Congo, and the other in a remote area of Sudan. It has since caused sporadic outbreaks across parts of Africa.

Viral classification: Ebola belongs to the Filoviridae family, a group of RNA viruses that can cause a Viral Haemorrhagic Fever.

Zoonotic nature: The origin of the virus is unknown but fruit bats are considered the likely host of the Ebola virus. It is believed to persist naturally in fruit bats between human outbreaks.

2. How the Virus Spreads

Direct contact: Ebola spreads through broken skin or mucous membranes coming into contact with infected bodily fluids.

Infectious fluids: The virus may be transmitted through blood, faeces, vomit, saliva, sweat, urine, breast milk, and semen.

Contaminated objects: Infection can occur through contaminated needles, bedding, clothing, or surfaces exposed to infectious fluids.

Animal exposure: Initial human infections may occur after handling or consuming infected bats, monkeys, chimpanzees, or other wildlife.

Important facts

• • Ebola does not spread through normal airborne transmission like measles or COVID-19.
  • Once a person comes into contact with an animal that has Ebola, it can spread within the community from human to human.
  • People cannot transmit Ebola before symptoms begin (unlike COVID-19).

Note. More information here on how Ebola spreads.

3. When to Worry – Early Symptoms to Watch For

Incubation period: Symptoms usually appear between 2 and 21 days after exposure, most commonly around 8 to 10 days later.

Fever: Early Ebola often begins with a rapid onset of high fever without another obvious explanation.

Body aches: Severe headaches, muscle pain, joint pain, and profound fatigue are common early features.

General illness: Patients may also develop chills, sore throat, weakness, and loss of appetite.

4. Advanced Symptoms and Disease Progression

Gastrointestinal illness: As the disease progresses, severe diarrhoea, persistent vomiting, nausea, and abdominal pain commonly develop.

Dehydration: Large fluid losses can rapidly cause dehydration, dangerously low blood pressure, and circulatory collapse.

Rash: Some patients develop a raised, non-itchy red rash affecting the torso and limbs.

Organ injury: Severe infection can result in acute liver injury, acute kidney injury (AKI), and widespread inflammation throughout the body.

5. Internal and External Bleeding

Clotting disruption: Ebola can interfere with the body’s blood-clotting mechanism (by causing a microangiopathy; see below), causing haemorrhage in severe cases.

External bleeding: Bleeding may occur from the gums, nose, eyes, or injection sites.

Internal bleeding: Patients may develop bruising, bloody stools, or vomit containing altered blood.

Severe disease: In advanced cases, haemorrhage combined with inflammation and organ failure may lead to fatal shock.

Important note: Despite the historic term ‘haemorrhagic fever,’ severe bleeding occurs only in a subset of Ebola patients.

6. High-Risk Groups

Healthcare workers: Medical staff face elevated risk if personal protective equipment (PPE) procedures fail.

Family caregivers: Relatives caring for infected patients without protective precautions are at significant risk.

Funeral and burial teams: Traditional burial practices involving direct physical contact with the deceased can spread infection efficiently.

Travellers and outbreak workers: People visiting or working in active outbreak regions may face increased exposure risk.

Pregnancy and children: Pregnant patients historically experience high maternal mortality and high rates of foetal loss. Children may also present differently from adults.

7. Assessing Your Risk

Dual-criteria rule: Concern is generally warranted only if both symptoms and a credible exposure history are present.

Travel history: Consider whether you travelled to an active outbreak region within the previous 21 days.

Contact history: Risk increases if you cared for an infected person, handled bodily fluids, or had exposure to potentially infected wildlife.

Common alternative illnesses: Without a relevant exposure history, rapid fever is statistically far more likely to be caused by infections such as influenza, COVID-19, or malaria.

8. When to See a Doctor Immediately

Fever after travel: Seek urgent medical advice if fever develops within three weeks of returning from an Ebola outbreak area.

Known exposure: Immediate medical assessment is essential after direct exposure to bodily fluids or contaminated objects linked to a suspected Ebola patient.

Emergency warning signs: Urgent care is required if symptoms progress to severe dehydration, confusion, bruising, bleeding, breathing difficulties, or collapse.

Public health importance: Rapid reporting helps health authorities isolate cases, trace contacts, and prevent wider transmission.

9. Medical Protocols and Isolation

Calling ahead: Patients should contact healthcare services before arrival so staff can prepare appropriate infection-control measures.

Isolation procedures: Suspected Ebola patients are managed in specialised isolation environments away from other patients.

Laboratory diagnosis: Confirmation depends on specialised PCR testing to detect Ebola viral RNA in blood samples.

Contact tracing: Public health teams rapidly identify and monitor anyone who may have interacted with an infected individual.

Prevention measures: Key prevention strategies include:

• Strict hand hygiene
• Avoiding contact with bodily fluids
• Safe burial practices
• Use of PPE
• Avoiding handling sick or dead wildlife in outbreak regions

10. Treatment, Vaccines, Survival, and Recovery

Supportive care: Early aggressive supportive treatment — including intravenous fluids, electrolyte replacement, oxygen, and blood pressure support — significantly improves survival. This can be very difficult to achieve in central Africa.

In previous outbreaks, there has been a WHO-coordinated response including military field hospitals set up by countries such as the US, UK and Germany. This may be needed in the current outbreak in the Congo.

Monoclonal antibody therapy: Modern antibody treatments such as Inmazeb and Ebanga can be highly effective against Zaire ebolavirus when given early.

Vaccination: Ring-vaccination strategies using vaccines such as Ervebo have been highly successful during outbreaks caused by the Zaire strain.

Mortality rates: Ebola is dangerous, but fatality rates vary substantially depending on viral strain, outbreak conditions, and access to medical care. WHO estimates:

• Average case fatality rate ≈ 50%
• Historical range ≈ 25–90%

Recovery and long-term complications: Many people survive Ebola infection, particularly with early supportive care. However, survivors may experience long-term complications including:

• Joint pain
• Chronic fatigue
• Eye inflammation (uveitis)
• Neurological symptoms
• Mental health difficulties

Persistence (e.g. in semen) after recovery: The virus can persist in certain body fluids — especially semen — for months after recovery, and rare cases of sexual transmission from survivors have been documented.

Six Major Ebolavirus Strains

The genus Ebolavirus consists of six distinct species, each named after its point of origin:

Affecting humans

• Zaire ebolavirus (EBOV): The most lethal and common strain, responsible for the devastating 2014–2016 West Africa epidemic.

• Sudan ebolavirus (SUDV): A highly virulent strain with numerous major outbreaks in East Africa.

• Bundibugyo ebolavirus (BDBV): The focus strain, known for lower average mortality but high transmissibility.

• Taï Forest ebolavirus (TAFV): Discovered in Côte d’Ivoire; has only caused a single non-fatal human case.

Probably do not affect humans

• Reston ebolavirus (RESTV): Found in the Philippines; infects primates and pigs but does not cause symptomatic disease in humans.

• Bombali ebolavirus (BOMV): Identified in Sierra Leone bats in 2018; its potential to infect humans remains unknown.

What are Viral Haemorrhagic Fevers?

Viral Haemorrhagic Fevers (VHFs) are severe illnesses caused by families of viruses (e.g. Ebola, Lassa, Marburg and Hanta).

VHFs damage the endothelium (inside of) small blood vessels (called a microangiopathy, or MAHA). This leads to bleeding, organ failure, and a high mortality rate.

Other causes of MAHAs include other infections/sepsis, TTP, HUS, DIC, some medications and cancers.

VHFs are primarily zoonotic, transmitted through contact with infected animals (bats (probably) f0r Ebola; rats for hantaviruses), mosquitoes, or ticks, with some spreading between humans.

Other Resources

Ebola Virus Factsheet

Hantavirus – 10 FAQs